Skip to content
HomeJanssen and Johnson & Johnson to Present Results from Five Pivotal Phase 3 Studies Evaluating Investigational Canagliflozin for the Treatment of Type 2 Diabetes

Janssen and Johnson & Johnson to Present Results from Five Pivotal Phase 3 Studies Evaluating Investigational Canagliflozin for the Treatment of Type 2 Diabetes

Share Article
share to

New Brunswick, NJ (June 5, 2012) – Janssen and Johnson & Johnson will provide investors and other interested parties an overview presentation of results from five pivotal Phase 3 studies evaluating investigational canagliflozin for the treatment of Type 2 Diabetes on Sunday, June 10 at approximately 2:00 p.m., Eastern Time. These data will be presented at the American Diabetes Association annual meeting in Philadelphia, Pa.

The presentation can be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com and clicking on “Webcasts/Presentations.”

###

Press Contacts:
Al Wasilewski
(732) 524-1130

Bill Price
(732) 524-6623

Investor Contacts:
Stan Panasewicz
(732) 524-2524

Louise Mehrotra
(732) 524-6491

You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.